Oncology and hematology research
The emergence of targeted oncology and hematology therapies for cancer and blood disorders has created tremendous hope for the millions of patients who suffer from these diseases, including the approximately 10 million people diagnosed with cancer worldwide each year. At the same time, the rapid pace of these advances has caused significant shortages of investigators and patients for biopharmaceutical companies developing novel cancer and hematology therapies. Fortunately, those companies can turn to PAREXEL for the expertise and resources to move their products through the development process quickly and efficiently so they can reach patients in need.
Oncology and hematology clinical research experience
PAREXEL’s experience and knowledge can make a substantial difference in helping you overcome the issues facing new cancer and hematology treatments. We have more than 30 trained oncologists and hematologists on staff – many of whom remain active in patient care and medical education. Equally important, PAREXEL has managed hundreds of oncology trials involving nearly 175,000 patients over the last five years, so we know what it takes to successfully bring these new therapies from the lab to the market. Those trials have encompassed many different classes of cancer therapeutics, including extensive work in cytotoxics, biologics, targeted therapeutics, immunotherapies, vaccine therapies, and supportive-care products. We also have one of the industry’s most extensive databases of investigators with oncology/hematology experience.
In addition, our development partners benefit from PAREXEL’s expertise in medical imaging technology, which is an increasingly important factor in demonstrating the efficacy and safety of oncology and hematology products. We have assembled one of the finest medical imaging groups in the world through Perceptive Informatics, our technology subsidiary. Our radiologists and medical oncologists ensure that your image acquisition protocols meet the latest requirements from regulatory authorities, such as blinded evaluation by independent oncologists. PAREXEL is also constantly investing in new technology to keep you at the forefront of imaging science. For example, we have pioneered the use of Dynamic Contrast Enhanced MRI for use in monitoring anti-angiogenesis and anti-vascular compounds.
Whatever your oncology/hematology development requirements, PAREXEL is right where you need us to advance your products for patients around the world.